Our Pipeline

Proprietary pipeline

We develop innovative therapeutics aimed at improving the lives of cancer patients. We have built a robust pipeline leveraging our small molecule expertise in targeted protein degradation, immuno-oncology, precision oncology, and epigenetics

Development stage
Program
MOA
Rights
Indications
Discovery
Pre-clinical
IND-enabling
Clinical Phase I
Clinical Phase II
Clinical Phase III

CA-170#
PD-L1/ VISTA antagonist

CA-170, Dual inhibitor of PDL1 and VISTA

Stage – Clinical Phase 3

 

CA-170 is an oral, small molecule dual inhibitor of PDL1 and VISTA. In contrast to antibodies, CA-170 offers the advantages of ease of dosing, the ability to manage immune-related adverse events (irAEs), and lower COGs.

Asia

NSCLC, bladder & kidney cancers

AUR-102

CDK7 inhibitor

AUR-102, CDK7 inhibitor

Stage – Clinical Phase 1

 

AUR-102 is a covalent inhibitor of CDK7. It is in clinical evaluation in patients with advanced solid tumors.

Global

Breast & prostate cancers, leukaemia

AUR-103
CD47 antagonist

AUR-103, CD47 antagonist

Stage – Clinical Phase 1

 

AU-103 is a highly differentiated oral small molecule inhibitor of CD47. In pre-clinical studies, AUR-103 does not show hemotoxicity. This is in contrast to anti-CD47 antibodies, where significant dose-limiting toxicities of anemia, thrombocytopenia, and leukopenia have been observed.

Global

Leukaemia, lymphoma and multiple solid tumors

AUR104

FABP5 inhibitor

AUR-104, First-in-class inhibitor of Fatty-Acid Binding Protein 5 (FABP5)

 

It is a first in class novel anticancer compound that inhibits FABP5 and affects the BCR pathway. It is in clinical evaluation as a monotherapy in patients with NHL and CLL who have progressed on prior standard therapies.

Global

Lymphoma and solid tumors

AUR-105
PRMT5 inhibitor

AUR-105, PRMT5 inhibitor

Stage – Clinical Phase 1

 

A substrate competitive inhibitor of PRMT5, with a high tumor/plasma ratio in xenograft studies. AU-105 has demonstrated significant efficacy in multiple pre-clinical cancer models.

Global

Leukaemia, lymphoma and multiple solid tumors

AUR-106
TIGIT antagonist

AUR-106, TIGIT antagonist

Stage – Clinical Phase 1

 

An oral, small molecule inhibitor of TIGIT and PDL1, developed from Aurigene’s small molecule IO platform. In contrast to antibodies, AUR-106 offers the advantages of ease of combination dosing, the ability to manage immune-related adverse events (irAEs), and lower COGs.

Global

Multiple cancers

AUR-107
CBP/p300 inhibitor

AUR-107, CBP/p300 inhibitor

Stage – IND-enabling

 

AUR-107 is an oral, dual inhibitor of CBP and p300 with excellent selectivity against other bromodomain containing proteins. The molecule has demonstrated excellent efficacy in pre-clinical models with good therapeutic margins.

Global

NSCLC, lymphomas, leukemias, bladder cancers and prostate cancers

AUR-108
DHODH inhibitor

AUR-108, DHODH inhibitor

Stage – Clinical Phase 1

 

AUR-108 (formerly known as AG-636) is an oral, potent DHODH inhibitor with high selectivity against a panel of dehydrogenases. It has broad activity in pre-clinical models of lymphoma and leukemia, with a potential for combination with standard of care.

Global

Leukaemia and lymphoma

AUR-109
DDR1/SIK2 inhibitor

AUR-109, DDR1/SIK2 inhibitor

Stage – Clinical Phase 2A

 

AUR-109 (formerly known as ODM-203) is an oral, spectrum selective kinase inhibitor targeting DDR1 and SIK2 along with clinically validated targets FGFRs and VEGFRs. It is currently being evaluated in FGFR mutant bladder cancer. The unique selectivity profile allows potential expansion of indications.

Global

Cancers of bladder, lung, breast, ovary, kidney, liver & lung fibrosis

AUR-101
RORgt inverse agonist

AUR-101, RORgt inverse agonist

Stage – Clinical Phase 2B

 

AUR-101 is an oral, small molecule RORgt inverse agonist. It is the most advanced clinical asset in this class, being developed for the treatment of moderate to severe psoriasis.

Global

Psoriasis, Psoriatic arthritis, Ankylosing spondylitis

Program
MOA
Rights
Indications
Discovery
Pre-clinical
IND-enabling
Clinical Phase I
Clinical Phase II
Clinical Phase III

MALT1 Inhibitor

Global

Lymphoma, R/R NHL, CLL

Selective SMARCA2

Global

SMARCA- 4 mutant cancers

Program
MOA
Rights
Indications
Discovery
Pre-clinical
IND-enabling
Clinical Phase I
Clinical Phase II
Clinical Phase III

Pan-KRAS

Global

Cancers of the lung, pancreas and colon

CDK 12/13 Inhibitor

Global

Breast, Ovarian and Prostate cancers

CCR4 antagonist

Global

Atopic dermatitis, Asthma and oncology

SMARCA2/4 dual degrader

Global

Prostate cancer, leukemia, lymphoma and myeloma

PDL1/A2AR dual inhibitor

Global

Multiple cancers

p300  selective degrader

Global

CBP mutant cancers, breast and prostate cancers

CBP selective degrader

Global

p300 mutant cancers

SMARCA2 oral degrader

Global

SMARCA- 4 mutant cancers

POLQ degrader

Global

Breast, prostate and multiple solid tumors

KIF18A inhibitor

Global

Ovarian, breast and other with high chromosomal instability

PKMYT1 inhibitor

Global

Cyclin-E amplified cancers

SIRPα/β*

Global

Multiple solid tumours

* Antibody programs

# Co-development programs with Aurigene leading clinical trials in India

Partnered Programs in Clinic

Here are the key compounds discovered at Aurigene in clinical development.

Partner
Target & Compound
Pre-clinical
Clinical Phase I
Clinical Phase II
Clinical Phase III

Novartis
(licensed to Laekna)

CYP17, CFG920

Astellas

PPARδ modulator, ASP0367

PPARδ modulator, ASP1128

Asana Biosciences

SYK/JAK, ASN002

BRAK/PI3K, ASN003

Japanese Pharma

Not disclosed

H3 Biomedicine

ESR1, H3B-6545

Curis

PD- L1/VISTA, CA170

IRAK4, CA4948

licensed/co-development programs

Notice: ob_end_flush(): failed to send buffer of zlib output compression (1) in /storage/v2188/aurigene-com/public_html/wp-includes/functions.php on line 5420

Notice: ob_end_flush(): failed to send buffer of zlib output compression (1) in /storage/v2188/aurigene-com/public_html/wp-includes/functions.php on line 5420